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Abstract 
 
The aim of this study is to investigate the function of the C-terminal extension of three troponin I 
isoforms, that are unique to the body wall muscles of Caenorhabditis elegans and to understand the 
molecular interactions within the TN complex between troponin I with troponin C/T, and 
tropomyosin. We constructed several expression vectors to generate recombinant proteins of three 
body wall and one pharyngeal troponin I isoforms in Escherichia coli. Protein overlay assays and 
Western blot analyses were performed using antibodies. We demonstrated that pharyngeal TNI-4 
interacted with only the pharyngeal isoforms of troponin C/T and tropomyosin. In contrast, the 
body wall TNI-2 bound both the body wall and pharyngeal isoforms of these components.  
Similar to other invertebrates, the N-terminus of troponin I contributes to interactions with troponin 
C. Full-length troponin I was essential for interactions with tropomyosin isoforms. Deletion of the 
C-terminal extension had no direct effect on the binding of the body wall troponin I to other muscle 
thin filament troponin C/T and tropomyosin isoforms.  
 
Abbreviations used: TN, troponin; TNI, troponin I; TNC, troponin C; TNT, troponin T; TM, 
tropomyosin 
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1. Introduction 
 
Muscle contraction is the result of a series of protein-protein interactions. In striated muscle, 
the thin filament complex of troponin (TN) and tropomyosin (TM) regulates contraction. The 
troponin complex components include the calcium-binding protein, troponin C (TNC), the 
tropomyosin (TM)-binding protein, troponin T (TNT) and troponin I (TNI) which is involved in 
inhibition of the actomyosin ATPase activity [1, 2]. Recent studies on crystals of the core TN 
complex suggest that in the absence of calcium, TNI-binding to actin holds the TN-TM complex in 
a “closed” state thereby preventing myosin from binding to actin [3, 4].  
Calcium ions (Ca2+) released into the muscle cells following neural stimulation bind to 
TNC, which undergoes a conformation change that alters its relationship with TNI, resulting in the 
release of TNI-binding to actin. Biochemical and physicochemical studies of muscle contraction 
have been carried out using proteins from different tissues of vertebrates. Multiple forms of troponin 
subunits have been identified in cardiac [5], slow skeletal [6] and fast skeletal muscles [7]. The 
detection of TNI isoforms by specific antibody staining provides a convenient and reliable method 
of muscle cell typing and the presence of TNI in serum can be used for the detection of disease in 
skeletal and cardiac muscles [8]. The immunological detection of serum cardiac TNI is widely used 
in cardiology as an index of myocardial damage [9]. Slow and fast isoforms are present in the same 
skeletal muscle cell as a consequence of cross innervations, hormone intervention, and in 
pathological conditions [10]. Thus, specific TNI isoforms probably play important roles in 
determining the distinctive functional properties of various muscle types from different animals. 
Specific amino acid sequences in muscle proteins have been shown to interact with specific 
sites. The first report on TNI fragments that bind TNC was done by Syska et al. [11]. They report 
that TNI fragment of the rabbit skeletal containing residues 1-21 and 96-116 bind TNC, and the 
latter also bind to actin. It has also been summarized in the rabbit skeletal TNT that the N-terminal 
residues 160-260 bound to TNC, and the C-terminal residues 216-263 might be the TNI interaction 
site[12]. Thus, specific interaction sites in the components form part of a functional complex. 
Comparisons of these amino acid sequences reveal that a high sequence homology of the 
TNC-binding site is present towards the N-terminal region of TNI isoforms containing N-terminal 
extensions that are seen in invertebrates and vertebrate hearts. It has been reported that 
bisphosphorylation of the N-terminal extension of human cardiac TNI alters the Ca2+-binding 
properties to TNC [13].  Similarly the high sequence homology of the actin/TNC-binding site 
exists within the central portions of TNI isoforms from many animals. These results of biochemical 
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studies were confirmed when atomic structures of the core TN complex recently became available 
[3, 4]. Probably, the regulatory complex of TN components shares common structural bases within 
the core complex but with some variation depending on muscle or animal type. Although many 
detailed analyses of interaction sites between the TN components still continues, few report on the 
overall interactions between regulatory components and include all isoforms derived from a single 
genome. 
TNI isoforms are expressed in two patterns: tissue specific and developmentally 
regulated. Previously, we have shown that three genes, namely, tni-1, tni-2/unc-27 and tni-3 are 
expressed in the body wall muscles, and that tni-4 exhibits pharyngeal-specific expression in 
Caenorhabditis elegans [14]. An approach to understand the role of TNI in the regulation of muscle 
contraction is to study the structural and functional differences between the various TNI isoforms. 
In our previous study, we also compared the amino acid sequences of four TNI isoforms of C. 
elegans with those of Drosophila, crayfish, and the cardiac, slow skeletal and fast skeletal muscles 
of rabbit [14]. Comparisons of these amino acid sequences reveal that a high sequence homology 
of the TNC-binding and the actin/TNC-binding sites exists in all C. elegans TNI isoforms. 
Interestingly, three body wall type TNI-1, TNI-2 and TNI-3 isoforms of C. elegans contain unique 
C-terminal extensions. C-terminal extensions containing approximately 20 glutamic acid residues 
are common in all body wall TNI isoforms but not in pharyngeal TNI isoform of C. elegans, the 
TNI isoforms of Drosophila, crayfish and rabbit [14]. The biological importance of the C-terminal 
extension remains unknown structurally and functionally.  
In this study, we focused on the importance of the C-terminal extensions of three body wall 
TNI isoforms as well as the tissue-specific interaction of TNI isoforms with other thin filament 
components. To investigate the interactions of the TNI isoforms and those fragments with other 
thin filament proteins, we constructed recombinant proteins of the N-, C-, and C-terminal 
extension-deletion fragments of TNI isoforms and performed Western blot analysis using 
antibodies. The C-terminal extensions had no direct role in the TNC, TNT and TM interactions. 
Molecular binding assays of TNI with other thin filament components provide an insight into how 
thin filament regulatory proteins evolved to specialize in their interactions to regulate muscle 
contractions. This is the first report on how the components of the TN complex of C. elegans 
interact with other thin filament components. 
 
- 5 - 
2. Materials and methods 
 
2. 1. Construction of expression vectors  
 
2. 1. 1. Construction of the N-terminal, C-terminal and C-terminal extension-deletions of the TNI 
expression vectors 
Expression vectors of the N- and C-terminal fragments of TNI-2, pCTNI-21–117 and 
pCTNI-2118–242 were constructed by inserting BamHI restriction fragments corresponding to a 354 
bp 5'-region and a 378 bp 3'-region of the tni-2 cDNA [14] into the BamHI site of pET-28a(+) 
vector, respectively. These restriction fragments were prepared by PCR amplification using tni-2 
cDNA as a template with the following sets of primers followed by BamHI digestion; TNI-2N-s 
(5'-AAG GAT CCA TGA GTG AAG AAG CCG GAG A-3') and TNI-2N-as (5'-AAG GAT CCG 
TTG ATG TCG TAC TTC TCC TCC-3') primers for pCTNI-21–117, and TNI-2C-s (5'-AAG GAT 
CCA TCA ACT ACG TCG TCT CCC AGA-3') and TNI-2C-as (5'-AAG GAT CCT GGA TTT 
AGG AGT TTA CTC CTC-3') primers for pCTNI-2118–242. pCTNI-294–242 was constructed by 
inserting a XhoI-HindIII restriction fragment corresponding to the  453 bp 3'-region of the tni-2 
cDNA into the XhoI-HindIII  site of  pET-28c(+) vector. The C-terminal extension-deletion 
construct of TNI-2 expression vector pCTNI-21-220 was constructed by inserting a BamHI 
restriction fragment corresponding to the 5'-region of the tni-2 cDNA, which is derived from the 
subcloned vector pGEX-CTNI-2 [14], into the BamHI site of the pET-28a(+) vector. This 
restriction fragment was prepared by PCR using pGEX-CTNI-2 as a template with pGEX5' 
(5'-GGG CTG GCA AGC CAC GTT TGG TG-3') and UNC-27-P2 (5'-TTG GAT CCT TAC 
TCA GCT TCT GGA GCA ACG-3') primers, followed by BamHI digestion. pCTNI-41-166 was 
constructed by inserting an EcoRI restriction fragment corresponding to the 530 bp 5'-half region of 
the tni-4 cDNA from yk328a10 into the EcoRI site of the pET-28b(+) vector. This restriction 
fragment was prepared by PCR using yk328a10 as a template with M13 (–21) and 
TNI-4-s-Eco-pETb (5'-GCG AAT TCA ACC ATG AGT GAC GTT GAC G-3') primers. Note that 
the TNI-4-s-Eco-pETb primer altered the stop codon in the 5' untranslated region (UTR) of the 
tni-4 cDNA.  pCTNI-491–194 was constructed by inserting an XhoI restriction fragment 
corresponding to the 519 bp 3'-region of the tni-4 cDNA from yk328a10 into the XhoI site of the 
pET-28b(+) vector.  
Expression vectors of other TNI-1/-3 isoforms were also constructed briefly as follows.  
pCTNI-11-126 was constructed by inserting an EcoRI restriction fragment of tni-1 cDNA from 
- 6 - 
yk103h4 into the EcoRI site of pET-28b(+) vector. pCTNI-1106-250 was constructed by inserting the 
XhoI restriction fragment of tni-1 cDNA from yk103h4 into the XhoI site of pET-28b(+) vector. 
pCTNI-31-125 was constructed by inserting an EcoRI restriction fragment of tni-3 cDNA from 
yk338a12 into EcoRI site of pET-28a(+) vector. pCTNI-3118-260 was constructed by inserting the 
BglII-XhoI restriction fragment of tni-3 cDNA from yk338a12 into BglII-XhoI site of pET-28c(+) 
vector. In summary, the N-terminal, C-terminal and C-terminal extension-deletion constructs of the 
TNI isoforms, as shown by the bars in Fig. 1, were cloned into the pET-28a(+), pET-28b(+) and 
pET-28c(+) vectors (Novagen), respectively and each of fragments were produced in E. coli strain 
BL21(DE3).  
 
2. 1. 2. Construction of the TNT-1, TNT-4, TNC and TM expression vectors 
 pCTNT-1 was constructed by inserting an EcoRI restriction fragment corresponding to 
the 1215-bp full-length tnt-1/mup-2 cDNA from yk1354g3 into the EcoRI site of the pET-28a(+) 
vector. This restriction fragment was prepared by PCR using yk1354g3 as a template with TNT-1-s 
(5'-TTG AAT TCA TGT CCG ACG AGG AGG AGG TAT AC-3') and TNT-1-as (5'-TTG AAT 
TCA TTC GAC AAC GAC CTC TTC TCC-3') primers, followed by EcoRI digestion. pCTNT-4 
was constructed by inserting a BamHI restriction fragment corresponding to the 1044-bp 
full-length tnt-4 cDNA from yk1174g10 into the BamHI site of the pET-28a(+) vector. This 
restriction fragment was prepared by PCR using yk1174g10 as a template with TNT-4-s (5'-CCT 
GGA TCC TCG ATG AAC ATG TCT GAC GAG GAA TAC TCC G-3') and TNT-4-as (5'-TCT 
GGA TCC TTA ATA GTC TTC CTC TTC CTC GGC-3') primers. The plasmid vectors for the 
bacterial expression of TNC-1 and TNC-2 have been described previously [14, 15].  
Some expression vectors of TNC, TNI and tropomyosin of C. elegans were used as 
reported previously (Table 1) [14-16]. TMI and TMIII expression vectors and the cDNA clones of 
CeTMI and CeTMIII were used as described previously [16]. All sub-cloned constructs were 
verified by DNA sequencing. 
 
2. 2. Western blot analysis and protein overlay assay  
 
Western blot analysis was performed using the ECL detection system (Amersham, now 
GE Healthcare Bio-Sciences) by using the following specific antibodies: anti-CeTMIII [16], 
anti-CeTNC-1/-2 [15] and anti-CeTNI-2/-4 [14]. Table 1 also describes the antibodies used in this 
study. Anti-CeTNC-1 and anti-CeTNC-2 were tissue-specific as they detected only body wall 
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TNC-1 and pharyngeal TNC-2, respectively (Fig. 2c) [14]. Anti-CeTMIII detected both the body 
wall TMI and the pharyngeal TMIII isoforms (Fig. 2d). Cross-reactivity of the TMI isoform with 
anti-CeTMIII, which was raised to detect the pharyngeal tropomyosin, TMIII isoforms, is due to 
the sharing of some amino acid residues from common exons [16, 17]. 
The body wall TNI-2 and TMI, and the pharyngeal TNI-4 and TMIII proteins of C. 
elegans were produced in E. coli strain JM109, which were transformed with each of cDNA 
expression vectors. cDNA clones of TNI-2/-4 and TMI/III were cloned into pGEX-4T series and 
pUR289, respectively [14,16]. The TNC-1 and TNC-2 proteins were produced in E. coli strain 
BL21 (DE3) transformed with the pCTNC-1 and pCTNC-2   vectors, respectively [15]. Note 
that the expressed proteins had no tag. TNT-1 and TNT-4 proteins were produced in E. coli BL21 
(DE3) transformed with the pCTNT-1 and pCTNT-4 vectors, which expressed His-tagged TNT-1, 
the body wall isoform, and TNT-4, the pharyngeal TNT isoform of C. elegans. Protein samples 
were prepared according to the standard procedure in which 0.05 µg/ml TNI, 0.02 µg/ml TNC, 
0.04 µg/ml tropomyosin and 0.05 µg/ml TNT were run on SDS-PAGE and blotted onto a nylon 
membrane. The processed membranes were immersed in 20 µg/ml TNI, 30 µg/ml TNC, 25 µg/ml 
tropomyosin and 50 mM Tris-HCl (pH 6.8) solution with 1 mM CaCl2 or 2 mM EGTA at 4 °C for 
12 hours. After washing, Western blot analysis was performed using 0.05 mg/ml rabbit polyclonal 
anti-CeTNI-2, anti-CeTNI-4, anti-CeTNC-1 and anti-CeTNC-2 antibodies, anti-CeTMIII 
anti-serum were used as the primary antibody, and 0.2 mg/ml of horseradish anti-rabbit IgG 
(Amersham Biosciences) was used as the secondary antibody; the samples were incubated at room 
temperature for 1 hour and analyzed by using the ECL detection system. 
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3. Results 
 
3. 1. Characterization of the fragments of the TNI, TNT and TM isoforms and their antigenic 
characters 
 
In C. elegans all isoforms of any muscle protein are identified and are available from the 
database, WormBase. We expressed several muscle thin filament proteins in E. coli by constructing 
expression vectors that are summarized in Table 1. We also constructed expression vectors to 
produce the N- and C-terminal fragments of three body wall isoforms (TNI-1, TNI-2 and TNI-3) 
and one pharyngeal isoform (TNI-4) (see Materials and methods; Fig. 1 and Table 1). The 
fragments consisted of two parts: the N-terminal fragment containing the TNC-binding site and the 
C-terminal fragment containing the actin/TNC-binding site. For example, deletion of the 
C-terminal extension fragment of TNI-2 was designated as TNI-21–220. The molecular sizes of the 
N-terminal TNI-21–117, C-terminal TNI-294–242, TNI-2118–242 and C-terminal extension- deletion 
TNI-21–220 fragments of the TNI-2 isoform were confirmed by SDS-PAGE (data not shown) and 
are summarized in Table 1. The products of these fragments were detected by Western blot analysis 
by using the anti-CeTNI-2 antibody that stained all four TNI isoforms of C. elegans (Fig. 2a) [14]. 
Size differences were observed in the fragments of the TNI isoforms due to the design of the 
expression vectors. We focused on the body wall TNI-2 isoform, a major known TNI component 
of the body wall muscle and the product of the tni-2/unc-27gene [14]. 
The expression vectors pCTNT-1 and pCTNT-4 expressed body wall TNT-1, a product of 
mup-2 [18] and pharyngeal TNT-4, a product of tnt-4, respectively. The molecular sizes of these 
recombinant proteins are summarized in Table 1. These proteins and other thin filament 
components were used in the molecular interaction experiments.  The anti-CeTNI-2 antibody, 
which was raised against the major body wall type, cross-reacted with all TNI isoforms, three body 
wall types and one pharynx type (Fig. 2a). This antibody also detected the N- and C-terminal 
fragments and the full length of all TNI isoforms; which suggested the presence of more than one 
recognition site in the TNI-2 isoform (Fig. 2a). As shown in Fig. 2b, the anti-CeTNI-4 antibody 
specifically detected the pharyngeal isoform, TNI-4. Fig. 2c shows that antisera against each of 
both the body wall type TNC-1 and the pharynx type TNC-2 isoforms had tissue specificity [14, 
15]. The recombinant proteins and antibodies produced in this study are summarized in Table 1 and 
Materials and methods.  
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3. 2. Molecular interactions of body wall and pharyngeal TNI isoforms with other thin filament 
components 
 
3. 2. 1. Interaction between TNI and TNC isoforms 
Both the TNC-1 and TNC-2 isoforms were overlaid on blotted N-terminal TNI-21–117, 
C-terminal TNI-294–242 and TNI-2118–242, and the C-terminal extension-deleted TNI-21–220 fragments 
in the presence or absence of Ca2+. Similar overlay experiments were also performed with the TNC 
isoforms and the pharyngeal TNI-41–166 and TNI-491–194 fragments. Each of the overlaid TNC 
isoforms was detected by using the anti-CeTNC-1 or anti-CeTNC-2 antibody (Fig. 3a-b). These 
results indicated that body wall TNC-1 bound specifically with the N-terminal body wall TNI-21–117 
fragment, but not with the pharyngeal TNI-4 isoform (Fig. 3a, upper and lower panels) [14]. 
Pharyngeal TNC-2 interacted with both the N-terminal TNI-21–117 and TNI-41–166 fragments and 
also the full-length TNI-2 and TNI-4 isoforms (Fig. 3b, upper and lower panels) [14]. The 
C-terminal extension-deleted TNI-21–220 fragment of body wall TNI-2 isoform was able to bind 
with both the TNC isoforms but both the C-terminal body wall TNI-294–242, TNI-2118–242 and 
pharyngeal TNI-491–194 fragments did not bind with either the body wall TNC-1 or pharyngeal 
TNC-2 isoforms, respectively (Fig. 3a-b). All interaction profiles between each pair of TNI and 
TNC isoforms are summarized in Fig. 3c. We concluded that the N-terminal body wall TNI-2 
interacted with both the body wall and pharyngeal TNC isoforms, but the N-terminal pharyngeal 
TNI-4 interacted only with pharyngeal TNC-2. 
The extent of the interaction varied among the TNI isoforms and the N-terminal fragment 
used depending on the presence or absence of Ca2+. However, it was difficult to determine whether 
these results reflect quantitative differences in these interactions. We hereafter focus on the TNI-2 
isoform to study the molecular interactions with other thin filament components from both the 
body wall and the pharynx. 
 
3. 2. 2. Interaction between TNI and TNT isoforms 
We performed protein overlay assays on full-length and fragmented body wall TNI 
isoforms with both body wall and pharyngeal TNT isoforms (Fig. 4). Full length TNI-2, the 
N-terminal TNI-21–117, the C-terminal TNI-294–242 and the C-terminal extension-deleted TNI-21–220 
fragments interacted with both the TNT isoforms (Fig. 4a, b, d and e) but the C-terminal 
TNI-2118–242   fragment did not (Fig. 4c).  
The full length TNI-4 and two fragments TNI-41–166 and TNI-491–194 bound only the 
- 10 - 
pharyngeal TNT-4 isoform (Fig. 4f–h). The results of the interaction of the TNI isoforms with the 
TNT isoforms in the presence or absence of Ca2+ were almost similar (data not shown). The 
interaction profiles between the TNI and TNT isoforms are summarized in Fig. 4i. In conclusion, 
the body wall TNI isoforms interacted with both the body wall TNT-1 and the pharyngeal TNT-4 
isoforms, but the pharyngeal TNI-4 only bound the pharyngeal TNT-4. The TNT interaction sites 
of four TNI isoforms in Fig. 1 were presented more details in Fig. 6a (see Discussion).  
 
3. 2. 3. Interaction between TNI and TM isoforms 
We further determined which of the TNI terminal regions interact with the tropomyosin 
isoforms of C. elegans. The pharyngeal TNI-4 isoform bound only to the pharyngeal tropomyosin, 
TMIII (Fig. 5b). Interestingly, the TNI-21–117, TNI-294–242, TNI-2118–242, TNI-41–166 and TNI-491–194 
fragments had lost the ability of the body wall and pharyngeal TNI isoforms to interact with 
tropomyosin isoforms (Fig. 5a-b). We conclude that body wall TNI-2 bound TNC/T and TM 
components from both tissues but pharyngeal TNI-4 interacted only with the pharyngeal 
components (Fig. 1). All the tissue-specific interactions of the TNI isoforms with other thin filament 
components are summarized in Fig. 1 (right panel) and are schematically shown in Fig. 6b (see 
Discussion). 
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4. Discussion 
 
By performing the protein overlay assays using antibodies as probes we have determined 
the molecular interactions of the body wall TNI isoforms with other thin filament components, 
TNC, TNT and TM. We obtained evidence that the pharyngeal TNI-4 isoform bound 
tissue-specifically with other thin filament components but that the body wall TNI isoforms 
interacted with these components from both tissues. The functional significance of the C-terminal 
extension, which is unique to the body wall TNI isoforms of C. elegans, was not found by this 
approach. 
 
4. 1. Molecular interactions among troponin components and tropomyosin 
 
4. 1. 1. Function of the C-terminal extension in the body wall TNI-2 isoforms 
In this study, we found that the N-terminal TNI-21–117, the C-terminal TNI-294–242, 
C-terminal extension-deleted TNI-21–220 and full-length TNI-2 all bound in a similar manner with 
both the body wall and pharyngeal TNT isoforms (Fig. 4a, b, d and e). The evidence obtained in 
this in vitro study confirmed that there was no difference in the interactions of body wall TNI 
isoforms with or without the C-terminal extension (Fig. 4d and e) and in the presence or absence of 
Ca2+ (data not shown). Similarly, the overlay assay results of TNC and TM isoforms also show that 
the C-terminal extension-deleted TNI-21–220 fragment is able to bind to both TNC and TM isoforms 
(Fig. 3a-b and Fig. 5a-b). Therefore, these results imply that the C-terminal extension has no direct 
role on binding to TNC, TNT and TM isoforms in C. elegans. Although we did not study the 
molecular interactions of the C-terminal TNI extension deletions of the two other body wall 
isoforms, the sequence similarity of the three TNI isoforms suggests that the C-terminal extension 
could have functions that were not detected by in vitro overlay assay. As the atomic structure of the 
core component of the human cardiac troponin complex does not include the TNI C-terminal 
region of this end of TNI [4], it could still have an important role in actin-myosin interactions. 
Tanaka et al. [19] reported that the ATNI232-292 C-terminal fragment of Akazara scallop TNI 
inhibited actomyosin-tropomyosin Mg-ATPase activity. Al-Hillawi et al. [20] also reported that the 
recombinant human cardiac TNI inhibited the acto-S1 Mg-ATPase activity. This inhibition was 
potentiated by the presence of tropomyosin and was reversed by the addition of the TNC to the 
system. Although we have not done experiments on the C-terminal extension to determine 
functional effects on ATPase activity, we assume that the C-terminal extension of the three body 
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wall TNI isoforms of C. elegans has some biological function.  
In muscle studies for C. elegans system [21], in vivo experiments could be used to 
determine the functional importance of the C-terminal extension. This might be achieved by 
studying whether the pharyngeal or C-terminal extension-deleted body wall TNI isoform could 
rescue the mutant phenotype of tni-2/unc-27 animals that have a mutation in the major body wall 
isoform gene, tni-2 [14].  
 
4. 1. 2. Molecular interactions between the TNI and TNT isoforms 
Immunoblotting, cross-linking and competitive labeling studies on the rabbit fast skeletal 
TNI and TNT suggest that the TNI 58-107 segment bound to TNT [22-24]. The atomic structure of 
the human cardiac troponin core complex shows that the helical part of H2 (I) interacted to H2 (T2) 
[4]. This region has been designated to the IT-arm [4]. We have focused on the IT-arm region, 
residue F90-R136 in human cardiac, of TNI in comparing residues among the four TNI isoforms 
of C. elegans and other animals (Fig. 6a) [14]. Our overlay assay results of the N-terminal 
TNI-21-117 and the C-terminal TNI-294-242 fragments of TNI-2 isoform suggest that TNI and TNT 
interaction sites are located in residues 94-117 (Fig. 1, Fig. 6a). The sequence alignment for the 
interaction sites in the four TNI isoforms of C. elegans (shaded in Fig. 6a) show that the interaction 
sites located in the N-terminal part of the IT-arms consist of three helical surfaces, three a and d 
surface of the heptad. In contrast to that, the pharyngeal TNI-4 isoform bound only with the 
pharyngeal TNT-4 isoform (Fig. 4f-h), whereas the body wall TNI-2 interacted with both tissue 
TNT isoforms (Fig. 4a, b, d, e and i). This suggests that the sites at which TNI and TNT interaction 
occurred contain some differences. From these results we assume that functional differences 
between the body wall and pharyngeal TNI isoforms came from deleting three amino acid residues 
in the pharyngeal isoform, TNI-4. The sequence alignment and the secondary structure prediction 
algorithm also suggest that this region can form a helical configuration. In the outside of the 
N-terminal of the helix, one proline residue is present in both TNI-1 and TNI-2 but two proline 
residues occur in TNI-3 and TNI-4. These will cause tilting of the helical rod of the IT-arm. 
Compared to the actin/TNC-binding sites of these TNI isoforms, the identity of TNT-binding sites 
among animals does not have a high sequence homology but there are some sequences homologies 
for forming helical conformations. Functional differences in the TNT-binding site between these 
animals may arise from fine-tuning the conformation of these regions between TNI and TNT. 
More detailed experimental studies on functional differences will be needed to investigate this 
further.  
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4. 1. 3. Molecular interactions of body wall TNI-2 with other thin filament components  
Our results that the pharyngeal TNI-4 only bound with the pharyngeal TNC-2 isoform but 
not with body wall TNC-1 (Fig. 3a-b) are similar to those in a previous report that the nature of the 
TNI and TNC interaction is very different in different organisms and tissues [19]. The result of our 
overlay assays of TNC binding to TNI isoforms implies that the N-terminal regions of both the 
TNI-2 and TNI-4 isoforms interacted with pharyngeal TNC-2 (Fig. 3a-b). Farah et al. [25] also 
reported that the N-terminal region of chicken skeletal muscle TNI bound to the C domain of TNC.  
The NMR structure of cardiac TNI reveals that the N-terminal fragments of cardiac TNI interact 
with the C-terminal region of cardiac TNC [2]. Therefore, our results suggest that the importance of 
the N-terminal region of TNI in interactions with TNC isoforms could be common in both 
vertebrates and invertebrates.  The reason why all C-terminal fragments of TNI did not to bind to 
TNC although they all contain actin/TNC-binding region could be the character of invertebrates. 
This was consistent to the case that molluskan Akazara scallop TNI232-292, which contained the 
actin/TNC-binding region, did not interact with TNC even in the presence of Ca2+ [19].  It is of 
interest to study how molecular interactions among TN complex are developed during evolution. 
Figure 5c summarizes the interactions between the two tissue-specific TNI and 
tropomyosin isoforms. These results suggest that the conformation of the TNI isoform altered after 
fragmentation, as the fragmented forms could not bind the tropomyosin isoforms (Fig. 5a-b). 
Similar results were observed in overlay assays of the tropomyosin and TNI isoforms in the 
absence of Ca2+ (data not shown). It has been reported that truncated troponin binds weakly to 
tropomyosin, regardless of Ca2+ presence [26]. Our results are consistent with this. It has also been 
reported that TNI binds weakly to tropomyosin in the presence or absence of Ca2+, whereas the 
TNI/TNC complex shows no detectable interaction with tropomyosin under similar conditions [27]. 
Thus, the direct binding of TNI with tropomyosin could be important in the regulation of muscle 
contraction. 
 
4. 2. Possible limitation of the protein overlay assay 
 
Although the yeast two-hybrid system is a well-characterized method for analyzing 
protein-protein interaction [28], it can only identify potential binding partners for a protein of 
interest; no information is provided about whether an interaction actually occurs in vivo or what the 
consequences of binding might be. Pull-down approaches [29] can reveal protein associations that 
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occur in a cell of interest, but still cannot address the functional consequences of those interactions. 
Thus, it remains difficult to identify those specific protein interactions that are functionally relevant 
to a biological activity of interest. Here, we show that protein overlay assays can be used to study 
molecular interactions between TNI and other thin filament components. This approach is more 
convenient than column chromatography. It is quicker and uses less equipment and protein. The 
degree of protein refolding, the antibody used as probe, and the order of overlaid or blotted proteins 
are important factors for success. Helical structures especially are easily recovered in the original 
structure and can interact with other proteins under the experimental conditions. Our results on 
Western analyses show that isoform specificities of each fragmented TNI isoform are detected by 
the corresponding antisera (Fig. 2). Depending on solubility or the size of proteins the interaction 
can vary. We designed our experiments so that the soluble and smaller proteins were overlaid onto 
blots of the less soluble or larger protein. Unfortunately we could not detect differences in protein 
binding in the presence or absence of Ca2+. It is difficult to control the quantities of the sample 
solution. Despite these limitations the overlay approach is a powerful means to determine the 
overall relationships between wide ranges of proteins from different sources. We have discussed in 
more details our use of this approach to study TNI isoforms and other thin filament components. 
 
4. 3. Gene duplication of thin filament components  
 
Based on the assay results of the interaction between TNI and TNC (Fig. 3), TNI and TNT 
(Fig. 4) and TNI and TM (Fig. 5) in this study,  we summarized the molecular interactions between 
these proteins in two tissues (Fig. 6b). Further, we observed the important fact that pharyngeal 
TNI-4 interacted only with other pharyngeal thin filament proteins, and not with the body wall 
proteins (Fig. 6b). We assume that this was due to evolutionary and functional reasons: Thin 
filament proteins expressed in the pharynx interacted with each other, as was observed in the 
overlay assay between the pharyngeal isoform pairs (step 1). In evolution, the body wall TNI gene, 
probably tni-3, duplicated subsequently, from tni-4 (step 2) [14]. Two other body wall TNI genes 
are likely duplicates of the original body wall TNI gene tni-3; this is also implied their tandem array 
on chromosome X. However, these genes do not differ considerably in their functions, although we 
have not determined this experimentally. These three body wall TNI isoforms can still interact with 
the pharyngeal isoforms (step 3). The body wall type genes of the thin filament components TNC-1, 
TNT-1 and tropomyosin TMI/II subsequently duplicated together with a mutation in the 
corresponding pharyngeal genes (step 4). The products of these genes could not interact with 
- 15 - 
pharyngeal TNI-4 because of the mutations that had occurred following gene duplication. Finally, 
the three body wall TNI isoforms could interact with the body wall TNC, TNT and TM isoforms 
(step-5). Troponin gene duplication during evolution and current isoform interactions can be 
explained in this manner. The sequence homology of the TNT-binding sites in the four TNI 
isoforms was lower than those of TNC- and actin/TNC-binding sites (Fig. 6a) [14]. Even with 
regard to the helical configuration of the TNI-TNT interaction site, the functional differences that 
depend on the type of amino acid residues of the isoforms could be important, although we have 
yet to determine any functional differences between these body wall isoforms. The hypothesis 
presented in this study will be useful to explore further the interactions within the troponin complex 
and other thin filament components in detail. 
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Figure legends 
 
Fig. 1. Schematic structures of four TNI isoforms and their constructed fragments and summary of 
their molecular interactions. The fragments containing the number of amino acids are shown in 
suffix. For example, the N-terminal fragment of TNI-1 containing amino acid residues 1-126 was 
TNI-11–126. Amino acid residue number follows to the previous report [14]. Highlighted boxes 
represent each location of the TNC-binding, TNT-binding, actin/TNC-binding and the C-terminal 
extension, respectively. More details for TNT-binding site are presented in Fig. 6a. The bar 
represents 50 amino acid residues. The right panel summarizes the molecular interactions of the 
constructed fragments of TNI isoforms with TNC, TNT and TM. BW, body wall; PHX, pharynx. 
“+” and “-” indicate a positive or negative interaction, respectively. 
 
Fig. 2. Specificity of the antiserum against TNI, TNC and TM of C. elegans. (a) Cross-reactivity of 
four TNI isoforms and their fragments with anti-CeTNI-2 antibody in Western blot analysis. The 
lanes contained the total protein of E. coli harboring the expression constructs containing the N-, 
C-terminal fragments of four TNI isoforms, C-terminal extension-deleted fragment of body wall 
TNI-2 and four full-length TNI isoforms (Table 1). (b) Cross-reactivity of four TNI isoforms with 
anti-CeTNI-4 antibody [14]. (c) Cross-reactivity of two TNC isoforms with the anti-CeTNC-1 and 
anti-CeTNC-2 antibodies [14]. (d) Cross-reactivity of the body wall tropomyosin TMI and the 
pharyngeal tropomyosin TMIII isoforms with anti-CeTMIII antibody in Western blot analysis [17]. 
The positions are indicated by the molecular size of marker proteins in kilo Daltons (kDa). Lane B 
contained the total proteins in E. coli BL21 (DE3).  
 
Fig. 3. Protein overlay assay of the body wall TNC-1 and the pharyngeal TNC-2 isoforms with 
both body wall TNI-2 and pharyngeal TNI-4 isoforms in the presence or absence of Ca2+. (a) 
Protein overlay assay of the TNC-1 isoform with the N- and C-terminal fragments of both TNI-2 
and TNI-4 isoforms in the presence of Ca2+ (upper panel) or absence of Ca2+ (lower panel). The 
overlaid TNC-1 isoform was detected by using the anti-CeTNC-1 antibody. (b) A similar protein 
overlay assay between the TNC-2 isoform and TNI isoforms or their fragments. Overlaid TNC-2 
was detected by using the anti-CeTNC-2 antibody. + Ca2+ and - Ca2+ indicates the presence and 
absence of Ca2+, respectively. (c) Summary of the interactions between the TNI and TNC isoforms. 
It was noted that the body wall TNC-1 only interacted with the N- terminal containing TNI-21–117 
fragment, C-terminal extension-deleted TNI-21–220 fragment and full-length TNI-2. 
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Fig. 4. Protein overlay assay between the body wall and pharyngeal TNI isoforms and both tissues 
TNT isoforms. Panels (a)-(h) demonstrate the results of the protein overlay assays; (a) TNI-21–117, 
(b) TNI-294–242, (c) TNI-2118–242, (d) TNI-21–220, (e) TNI-2, (f) TNI-41–166, (g) TNI-491–194 and (h) 
TNI-4 isoforms with both the body wall and pharyngeal TNT isoforms. The arrowheads indicate a 
52-kDa TNT-1 and a 45-kDa TNT-4. Asterisks indicate no interaction with respective TNT 
isoforms. The overlaid TNI-21–117, TNI-294–242, TNI-2118–242, TNI-21–220 and TNI-2 fragments were 
detected by using the anti-CeTNI-2 antibody, and the overlaid TNI-41–166, TNI-491–194 and TNI-4 
fragments were detected by using the anti-CeTNI-4 antibody. (i) Summary of interactions between 
the TNI and TNT isoforms.  
 
Fig. 5. Protein overlay assay of body wall TMI and pharyngeal TMIII with both the body wall 
TNI-2 and pharyngeal TNI-4 isoforms. (a) Protein overlay assay of the TMI isoform with the N- 
and C-terminal fragments of both TNI-2 and TNI-4 isoforms and the C-terminal extension-deleted 
fragment TNI-21–220.  (b) A similar assay of the TMIII isoform with those of TNI isoforms. 
Overlaid TMI and TMIII were detected by using the anti-CeTMIII antibody. (c) Summary of 
interactions between TNI and TM isoforms obtained from the results of (a) and (b).  
 
Fig. 6. Alignment of the TNT-binding site of the TNI isoforms of invertebrates and vertebrates and 
the molecular interaction model. (a) Sequence comparison of the TNT-binding sites of four TNI 
isoforms of worms and those of Akazara scallop, crayfish, Drosophila, Ciona heart and body wall, 
rabbit cardiac, human cardiac, rabbit slow, human slow, rabbit fast and human fast skeletal muscles. 
The shade indicates the TNT-binding site of the TNI-2 isoform. The box indicates the IT-arm of the 
human cardiac TNI [4]. The black bars represent the (H2) TNI helix region [4] and TNT-binding 
site, respectively. Numbers in the TNT-, TNC- and actin/TNC-binding sites represent percentage 
homology. Data follows the previous report [14]. Hydrophobic amino acids locating at the ‘a’ and 
‘d’ positions in the heptads repeat are located at the top of the sequence. The identity and similarity 
of the amino acid residues are indicated by (*) and (:/.), respectively. (b) The molecular interaction 
model to study the interactions between the TNI isoforms and those with the other thin filament 
components TNC, TNT and TM. Step 1 represents the interaction of the pharyngeal TNI-4 isoform 
with that of pharyngeal TNC-2, TNT-4 and TMIII; Step 2 represents the presumably gene 
duplication of pharyngeal TNI-4 to the body wall TNI isoforms; Step 3 represents the interaction of 
the body wall type TNI isoforms with other pharyngeal thin filament proteins (as mentioned in step 
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1); Step 4 represents presumably gene duplication with mutations of pharyngeal isoforms to their 
corresponding body wall isoforms; Step 5 represents the interaction of the body wall troponin and 
tropomyosin isoforms with the body wall TNI isoforms, respectively. The rectangles and circles 
indicate the body wall and pharynx specific isoforms, respectively. 
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BW, body wall; PHX, pharynx; ND, not determined; amolecular size on SDS-PAGE; bRuksana et al.[14];  
 
cTerami et al. [15];  dWormBase; eKagawa et al.[16]; fProducts are used for the production of antibody. 
 
 Table 1 
Construction  and expression  of TNI, TNC, TNT  and TM
pCTNI-11-126 TNI-11-126 126  23 
pCTNI-1106-250
ND
TNI-1106-250
pCTNI-2 TNI-2f 
pCTNI-21-117 TNI-21-117
pCTNI-294-242 TNI-294-242
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Fig. 3 Amin et al.
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Fig. 4 Amin et al.
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Fig. 5 Amin et al.
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Fig. 6 Amin et al.
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                                 a  d   a  d   a  d   a  d   a  d   a  d   a  d          TNT  TNC  Actin/TNC 
CeTNI-1 BW        92 TVALPNVDSIDDHAKLEAIYNDLFSRLCNLEEEKYDINHITTETETTINQLNIEVNDLR 150     100  100  100 
CeTNI-2 BW        80 TISLPNVDSIDDKGQLEKIYNDLWARLTQLEEEKYDINYVVSQTEAEINSLTIEVNDLR 138      72   81  100 
CeTNI-3 BW        92 TIPLPDVDSINDQGQLLKIYEDMFARVCALEEEKFDINFGVSQTEAEINQLTIQVNDLR 150      59   71   94 
CeTNI-4 PHX       79 IIPLPDLDNEDD---LEAVYDEIRERLIDLESENYDVSYIVRQKDFEINELTIAVNDLR 134      48   75   94 
Akazara scallop  183 VPKFS--TDGKDVAALQALCKDFHKRLASLEEDVYDWEAKIRKQDFEINELTLKVNDTK 239      41   40   65 
Crayfish          80 CGQPKNLDGANEE-QLRAIIKEYFDHTAQIESDKYDVELEIIRKDYEINELNIQVNDLR 137      31   60   88 
Drosophila        78 CGSPRNLSDASED-TLKSLIKQHYDRINKLEDQKYDLEYVVKRKDVEINDLNAQVNDLR 135      24   60   94  
Ciona   heart     96 LEPLSG-LNSMSSQELMDLCRELHGKIDKVDEQRFDIEARVKKNDTEIEELNQKIFDLR 153      14   31   47 
Ciona   BW        49 LEPLSG-LNSMSSQELMDLCRELHGKIDKVDEQRFDIEARVKKNDTEIEELNQKIFDLR 106      14   27   53 
Rabbit  cardiac   80 CQPLE--LAGLGFAELQDLCRQLHARVDKVDEERYDVEAKVTKNITEIADLTQKIFDLR 136      28   19   53 
Human   cardiac   80 CQPLE--LAGLGFAELQDLCRQLHARVDKVDEERYDIEAKVTKNITEIADLTQKIFDLR 136      28   27   47   
Rabbit  slow      46 IPALQ--TRGLSLSALQDLCRQLHAKVEVVDEERYDIEAKCLHNTREIKDLKLKVLDLR 102      21   25   53 
Human   slow      49 IPTLQ--TRGLSLSALQDLCRELHAKVEVVDEERYDIEAKCLHNTREIKDLKLKVMDLR 105      21   31   53 
Rabbit  fast      50 CPPLS--LPGS-MAEVQELCKQLHAKIDAAEEEKYDMEIKVQKSSKELEDMNQKLFDLR 105      25   23   53 
Human   fast      50 CPPLH--IPGS-MSEVQELCKQLHAKIDAAEEEKYDMEVRVQKTSKELEDMNQKLFDLR 105      25   22   53 
                                    :  :  :   :    :.: :* .    .    : .:.  : * :
 
 
